menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Blocking IL1α Protein Decreases Severity of Inflammation in Crohn’s Disease

Blocking IL1α Protein Decreases Severity of Inflammation in Crohn’s Disease
12/18/2019
news-medical.net

News-Medical.net

Investigators at the Case Western Reserve University School of Medicine discovered that blocking interleukin-1α (IL1α), a protein that controls inflammation in the gut, markedly decreases the severity of intestinal inflammation in a mouse model of Crohn's disease (CD).

The anti-inflammatory effects of the biological therapies used to neutralize IL1α were similar to those of steroids, which represent what is generally considered the gold standard of treatment for these patients.

In addition, the researchers found that the effect of anti-IL1α treatment was controlled by changing the composition and function of the gut microbiome.

Their findings will be published online the week of Dec. 16 in the Proceedings of the National Academy of Sciences.

"This is one of the first studies, to our knowledge, that links the effect of a specific cytokine, such as IL1, to the gut microbiome," said lead author Fabio Cominelli, professor of medicine and pathology at Case Western Reserve University, and division chief of gastroenterology at University Hospitals Cleveland Medical Center.

Furthermore, the study provides the preclinical rationale for performing the first clinical trial blocking interleukin-1 in patients with inflammatory bowel disease (IBD), which Cominelli and his collaborators at Xbiotech Inc., a biosciences company based in Austin, Texas, who developed a human monoclonal antibody against IL1α, are planning for the near future.

IBD, which refers to Crohn's disease and ulcerative colitis, affects more than three million adults in the United States, according to the Centers for Disease Control and Prevention.

This estimate does not include children who may also have IBD. Most people with IBD are diagnosed in their 20s and 30s, according to the CDC.

These ailments are chronic, relapsing, inflammatory conditions of the gastrointestinal system characterized by severe pain, diarrhea, bleeding and sometimes intestinal complications requiring surgery.

To date, there is no cure for these devastating diseases, and available therapies are effective in only about half of IBD patients.

"Therefore, there is a great need for developing new biological therapies, such as anti-IL1 monoclonal antibodies," Cominelli said.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 3/8/21